KAI 1678 is a first-in-class, isoenzyme selective, a small peptide inhibitor of protein kinase C epsilon. It was in development for the treatment of neuropathic and postoperative pain. However, KAI-1678 treatment results were negative.
Official Title: A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Postherpetic Neuralgia, Purpose: The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postherpetic neuralgia pain, Primary Outcome Measures: The effect of KAI-1678 on mean change from baseline in pain intensity at 6 hours (PID 6). (Time Frame: Day 1) (Designated as safety issue: No) Measurements are made using a qualified pain scale and the change from basline is calculated at 6 hours.
Originator: KAI Pharmaceuticals; Developer: Amgen; Class: Anti-inflammatory,Non-opioid analgesic, Peptide, Small molecule; Mechanism of Action: Protein kinase C epsilon inhibitor; Highest Development Phase: Discontinued for Neuropathic pain, Postoperative pain; Most Recent Events: 05 Jul 2012 KAI Pharmaceuticals has been acquired by Amgen, 22 Apr 2010 KAI Pharmaceuticals completes a phase IIa trial (NCT01106716) in Neuropathic pain in Australia, 21 Oct 2009 Pharmacodynamics data from a preclinical study in Neuropathic pain presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
KAI-1678, First-in-Class Compound, Enters Phase 2a Clinical Testing for the Treatment of Pain: KAI-1678 is an isozyme-selective, small peptide inhibitor of the epsilon protein kinase C pathway. Epsilon PKC is a well-validated target for both inflammatory and neuropathic pain in the preclinical, peer-reviewed scientific literature. KAIs approach is the first to enable the specificity of action required to make epsilon PKC inhibition a viable clinical approach.
KAI-1678 has been shown to be highly effective at reversing pain in preclinical models of both neuropathic and inflammatory pain.
